Nanobiotix Unveils Promising Preclinical Data on its Nanoprimer Platform at AACR
Nanobiotix announced on Monday the presentation of new preclinical data evaluating its nanoprimer platform combined with DNA immunotherapies delivered through lipid nanoparticles. These results were presented at the Annual Meeting of the American Association for Cancer Research (AACR).
Addressing a Major Challenge in DNA-LNP Therapies
The study focuses on a significant constraint of DNA-LNP therapies: rapid hepatic elimination via the mononuclear phagocyte system, which reduces the systemic bioavailability of DNA and increases hepatic toxicity. In a murine model, DNA-LNPs designed for antitumor immunotherapy were administered with or without nanoprimer pretreatment. The nanoprimer technology is designed to transiently occupy hepatic clearance pathways to increase bioavailability and accumulation in target tissues while reducing hepatic toxicity.
Nanoprimer Platform: Enhancing Drug Bioavailability
The nanoprimer platform is a preclinical nano-therapeutic platform designed to enhance drug bioavailability while reducing off-target adverse effects, including hepatic toxicity. It can be used with most intravenously administered therapies across different drug classes. Nanobiotix is developing this platform through strategic external collaborations alongside an internal proprietary pipeline of assets compatible with nanoprimer technology.
